Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 13, Pages 2407
Publisher
MDPI AG
Online
2019-07-01
DOI
10.3390/molecules24132407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of a Novel Dual Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin (mTOR) Target Inhibitor as a Promising Strategy for Cancer Therapy
- (2019) Yong Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies
- (2019) Xuewu Liang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo
- (2018) Ye Wei et al. ANTI-CANCER DRUGS
- Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously
- (2018) Jie Zang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
- (2018) Shipeng He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor
- (2018) Zhong-Rui Li et al. BIOORGANIC CHEMISTRY
- Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
- (2017) Harun Patel et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
- (2017) Rong-geng Fu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma
- (2016) Victor Jeannot et al. OncoTargets and Therapy
- Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells
- (2016) Shirong Zhang et al. Oncotarget
- Perspectives in the development of hybrid bifunctional antitumour agents
- (2015) Loana Musso et al. BIOCHEMICAL PHARMACOLOGY
- The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
- (2015) Gabriele Greve et al. BMC CANCER
- Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy inEGFR-Mutant Lung Cancer: A Meta-Analysis
- (2015) Chee Khoon Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer
- (2015) Wei Sun et al. Journal of Hematology & Oncology
- EMT, CTCs and CSCs in tumor relapse and drug-resistance
- (2015) Abhisek Mitra et al. Oncotarget
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity
- (2014) Xiaoyang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Polypharmacology: Challenges and Opportunities in Drug Discovery
- (2014) Andrew Anighoro et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains
- (2013) Mathew P. Martin et al. ACS Chemical Biology
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Triazole–Dithiocarbamate Based Selective Lysine Specific Demethylase 1 (LSD1) Inactivators Inhibit Gastric Cancer Cell Growth, Invasion, and Migration
- (2013) Yi-Chao Zheng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Polypharmacology – Foe or Friend?
- (2013) Jens-Uwe Peters JOURNAL OF MEDICINAL CHEMISTRY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Lysine Demethylases Inhibitors
- (2011) Takayoshi Suzuki et al. JOURNAL OF MEDICINAL CHEMISTRY
- Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
- (2011) Fenlai Tan et al. LUNG CANCER
- HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
- (2011) Chia-Wei Chou et al. PLoS One
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC)
- (2009) S. E. Witta et al. ANNALS OF ONCOLOGY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started